Pharmaceutical

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Ovarian Cancer.

Apr 23, 2024 - 00:00
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Ovarian Cancer.
Read the original article

Tags:

Previous Article

Datopotamab deruxtecan by Daiichi Sankyo for Transitional Cell Carcinoma (Urothe...

Next Article

Datopotamab deruxtecan by Daiichi Sankyo for Non Muscle Invasive Bladder Cancer ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Ted Love, BIO’s first Black board chair, aims to rehab biotech’s image in Washington

STAT+: Ted Love, BIO’s first Black board chair, aims to...

Jun 6, 2023

Crossject secures funding from French Government for needle-free platform

Crossject secures funding from French Government for ne...

Jul 14, 2024

STAT+: Viking Therapeutics obesity drug hits target in key study, raising hopes for a competitor to existing medicines

STAT+: Viking Therapeutics obesity drug hits target in ...

Feb 27, 2024